Company: AZN
Filing Date: 2025-09-29
Form Type: 6-K
Source: 0001104659-25-094039
Chunk: 2

Company: ASTRAZENECA PLC
Filing Date: 2025-09-29
Form: 6-K
Chunk 2
---
2026                   | ​ |
| ​ | Expected time and date for commencement of trading in AstraZeneca Shares and AstraZeneca US Bonds on the NYSE                                               | ​ | ​ | By 8:00 a.m. (ET)                 
 on 2 February 2026                | ​ |
| ​ | Expected date for the issuance of AstraZeneca DIs to relevant CREST participant accounts                                                                    | ​ | ​ | On or around 2 February 2026      | ​ |
| ​ | Expected date for the issuance of statements of entitlement for existing CSN Eligible Certificated Shareholders and CSN Participants                        | ​ | ​ | By no later than 16 February 2026 | ​ |

NOTES: (1) All dates and times are based on AstraZeneca’s current expectations and are subject to change. If any of the dates and/or times change, AstraZeneca will give notice of the change by issuing an announcement through a Regulatory News Service. (2) Note that different deadlines apply to holders of Swedish Listed Shares and AstraZeneca ADSs and to existing CSN Participants, who should refer instead to the Notes to the Notice of General Meeting included in this document and any other documentation made available to them. In the event that the General Meeting is adjourned, not later than 48 hours (excluding any part of any day that is a non-working day) before the time fixed for the adjourned General Meeting. (3) Only those Shareholders entered on the Register of Members at 6:30 p.m. (GMT) on 30 October 2025 or, if the General Meeting is adjourned, on the Register of Members at 6:30 p.m. (GMT) on the day and time which is not more than 48 hours before the time of the adjourned meeting, (or, in each case, their Nominated Persons) shall be entitled to attend and vote at the General Meeting in respect of the number of AstraZeneca Shares registered in their name at that time. Please note that a different record time applies to holders of Swedish Listed Shares and AstraZeneca ADSs, who should refer to the separate documentation made available to such persons for further information.

2

TABLE OF CONTENTS

### IMPORTANT NOTICES

#### 1.

#### General
The contents of this document are not to be construed as legal, business or tax advice. Recipients of this document should consult their own legal adviser